<DOC>
	<DOC>NCT02245958</DOC>
	<brief_summary>This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.</brief_summary>
	<brief_title>A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm</brief_title>
	<detailed_description />
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years Treatment with Xeomin® and BOTOX® for at least 2 years each. Having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission Previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>